Currently Viewing:
Newsroom
Currently Reading
Similar Incidence Rates of Febrile Neutropenia Between Short- and Long-Acting G-CSFs
December 26, 2018 – David Bai, PharmD
Severe Neutropenia May Predict Survival Outcomes in Patients With Pancreatic Cancer
December 05, 2018 – David Bai, PharmD
Management and Prevention of Febrile Neutropenia: Updated Guidelines
November 30, 2018 – Jaime Rosenberg
Outpatient ASCT Safe, Results in Lower Rates of Febrile Neutropenia and Septicemia
November 29, 2018 – David Bai, PharmD
Congenital Severe Neutropenia Presents With Different Clinical, Hematological Findings Than Noncongenital Neutropenia
November 21, 2018 – David Bai, PharmD
Assessment Can Help ED Physicians Predict Poor Prognosis for Patients With Febrile Neutropenia
November 16, 2018 – Jaime Rosenberg
Study Identifies High Burden of Invasive Infections in Neutropenic Patients
November 14, 2018 – Jaime Rosenberg
Characteristics and Management of Patients With Febrile Neutropenia
November 09, 2018 – David Bai, PharmD
AJMC® in the Press, November 9, 2018
November 09, 2018 – AJMC Staff

Similar Incidence Rates of Febrile Neutropenia Between Short- and Long-Acting G-CSFs

David Bai, PharmD
Incidence of febrile neutropenia, hospitalizations, and chemotherapy dose reductions and/or delays were similar between short- and long-acting granulocyte-colony stimulating factors, according to a meta-analysis of randomized controlled trials.
Incidence of febrile neutropenia, hospitalizations, and chemotherapy dose reductions and/or delays were similar between short- and long-acting granulocyte-colony stimulating factors (G-CSFs), according to a meta-analysis of randomized controlled trials (RCTS).

The use of prophylactic agents such as G-CSFs has decreased the duration of neutropenia, optimizing chemotherapy outcomes and decreasing the risk of febrile neutropenia. Short-acting G-CSFs (filgrastim) are administered daily for up to 2 weeks or until absolute neutrophil count reaches 10,000/mm3, while long acting G-CSFs (pegfilgrastim) are administered once every 2 to 3 weeks, depending on the chemotherapy cycle.

In previous observational studies, neutropenia-related outcomes were found to be generally lower for long-acting G-CSFs than short-acting G-CSFs. To verify or refute these findings, researchers performed a meta-analysis on RCTs and non-RCTs reporting reduction of febrile neutropenia from G-CSFs.

Of the 36 studies, 11 RCTs and 13 non-RCTs evaluated the incidence of febrile neutropenia in short- and long-acting G-CSFs. Results from all the RCTs and 6 non-RCTs revealed no statistically significant differences in the incidence of febrile neutropenia between short- and long-acting G-CSFs. Overall risk for febrile neutropenia for the RCTs demonstrated that the risk was generally lower for long-acting G-CSFs than with short-acting G-CSFs, although the difference was not statistically significant (P = .226).

Of the remaining non-RCTs, 5 reported long-acting G-CSFs to be significantly superior. Overall risk for febrile neutropenia of non-RCTs in the meta-analysis followed similar trends of superiority of long-acting G-CSFs; however, the difference was statistically significant (P = .023).

Among the 5 RCTs that reported incidence of hospitalizations, none of them found significant differences between short- and long-acting G-CSFs. However, of the 15 non-RCTs, 9 of them reported significantly lower hospitalizations for long-acting G-CSFs compared with short-acting G-CSFs. Hospitalizations due to febrile neutropenia were also generally lower in the long-acting G-CSFs in the meta-analysis of non-RCTs (relative risk [RR] = 0.68; P < .05). Not enough RCTs reporting incidence of hospitalizations were available for a meta-analysis.

Dose reductions and/or delays were similar between short- and long-acting G-CSFs in the 4 RCTs that reported dose reductions due to neutropenia. In the 10 non-RCTS that reported dose reductions from neutropenia, 2 reported higher incidence of dose reductions and/or delays with short-acting G-CSFs. Overall risk of chemotherapy delays from the meta-analysis of non-RCTs showed lower risks with long-acting G-CSFs compared with short-acting G-CSFs (RR= 0.68; P = .02). Not enough RCTs reporting dose reductions were available for a meta-analysis.

Although there was a trend in favor of long-acting G-CSFs in non-RCTs, these results could have simply come from underdosing short-acting G-CSFs, according to the researchers. In RCTs, where short-acting and long-acting G-CSFs were dosed according to recommended guidelines, the results were similar, suggesting no clinical differences between short- and long-acting G-CSFs. 

Reference:

Cornes P, Gascon P, Chan S, et al. Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther. 2018;35(11):1816-1829. doi: 10.1007/s12325-018-0798-6.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up